Clinical trials: Schizophrenia and Disorders With Psychotic Features
Psychosis, Psychotic Disorders
Imagery Rescripting as a Treatment for Early Psychosis
The goal of this multiple baseline case series study is to test the effect of imagery rescripting (ImRs) in early psychosis. Primary objective :The course of schema or core beliefs, wellbeing and self-esteem in early psychosis.
- Conditions
- Psychosis, Psychotic Disorders, Schizophrenia, Psychoses, Traumatic
- Trial name
- NCT06539780
- Testing
- Imagery Rescripting
- Where
- Netherlands
- Volunteers
- 8 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Mental Disorder
Do Consumer Providers Enhance Recovery?
Serious mental illness (SMI) is the second most costly disorder treated in the VHA, yet clinical outcomes for these patients in public sector settings are often poor due to a combination of low quality care and severe cognitive…
- Trial name
- PEER (NCT00781079)
- Testing
- Consumer Provider
- Where
- 7 sites in United States
- Volunteers
- 285 people
- Sponsor
- VA Office of Research and Development
Mindfulness Training
MBRS-Based Psychoeducation in Patients With Schizophrenia
This study aimed to determine the effects of mindfulness-based stress reduction training on anger management and functional recovery in patients with schizophrenia.
- Trial name
- NCT07130227
- Testing
- Session 1: Preparatory Session, Session 2: Mindfulness, Session 3: Our Perspectives on Ourselves and the World
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Ataturk University
Schizophrenia
Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia
This study is a 6-month, multicenter, randomized study to assess the effect of daily SMS reminders sent during 3 months in the adherence to oral antipsychotic treatment in stabilized outpatients with schizophrenia.
- Trial name
- SMS (NCT00873249)
- Where
- 25 sites in Spain
- Volunteers
- 339 people
- Sponsor
- AstraZeneca
Schizophrenia
Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants
The purpose of this study is to characterize the safety and tolerability of TAK-063 when administered as multiple oral doses at escalating dose levels in participants with stable schizophrenia and in healthy Japanese participants.
- Trial name
- NCT01879722
- Testing
- TAK-063
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Takeda
Schizophrenia, Psychosis
Searching for Early Biomarkers of Long-term Hepatic, Metabolic and Endothelial Dysfunction in Non-affective Psychosis
This study aims to evaluate, at long-term, the occurrence of liver disease and cardio-vascular risk, in a sample of patients diagnosed with first episode of non-affective psychosis.
- Conditions
- Schizophrenia, Psychosis, Metabolic Syndrome
- Trial name
- NCT03481465
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundación Marques de Valdecilla
Schizophrenia, Schizophreniform Disorder
A German Multicenter Study on Toxoplasma Gondii in First-episode Schizophrenia
Environmental risk factors for the development of schizophrenia include infections during the perinatal period or later in life with Toxoplasma gondii (TG) being one of the candidate agents.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- NCT00686400
- Testing
- TAU = treatment as usual
- Where
- 3 sites in Germany
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Schizophrenia, Schizoaffective Disorder
A Randomised Controlled Trial of Coenzyme Q10 in Patients With Schizophrenia and Schizoaffective Disorder
The study is a randomised placebo controlled trial of Coenzyme Q10 (CoQ10) vitamin supplementation in a sample of patients with schizophrenia or schizoaffective disorder.
- Trial name
- NCT03576911
- Testing
- Coenzyme Q10
- Where
- Ireland
- Volunteers
- 72 people
- Sponsor
- University of Dublin, Trinity College
Schizophrenia
Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia
The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate compared to placebo in the treatment of the symptoms of schizophrenia in adults.
- Trial name
- NCT00101634
- Testing
- Paliperidone palmitate
- Volunteers
- 518 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of flexible-doses paliperidone ER (3 to 12 mg as needed) compared with placebo over 3 weeks in patients with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00309699
- Testing
- Quetiapine, Paliperidone ER
- Where
- 47 sites in United States, Greece and 6 more
- Volunteers
- 493 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Mental Illness, Chronic Physical Illness
Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project
The Wellness Incentives and Navigation (WIN) project is designed to help improve health self-management and reduce the incidence and consequences of chronic disease among non-elderly adult Medicaid Supplemental Security Income…
- Trial name
- WIN (NCT02440906)
- Testing
- Patient-Directed Wellness Account, Health Navigator
- Where
- United States
- Volunteers
- 1,663 people
- Sponsor
- University of Florida
Emotional Dysregulation
Patients Suffering From Emotional Dysregulation
Emotional dysregulation (ED) is a common syndrome in psychiatric disorders. It is characterized by intense emotions, easily triggered, and with significant psychological impact: explosions of anger, irritability, impulsivity…
- Trial name
- Dys-Emotion (NCT06616337)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Schizophrenia
Effects of Motivating People With Schizophrenia to Exercise
This study will evaluate the impact of motivational guidance to exercise on people with schizophrenia, based on their participation in a walking program.
- Trial name
- NCT00559572
- Testing
- Motivational group sessions, Time and attention control group sessions
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- The University of Tennessee, Knoxville
Treatment-resistant Schizophrenia
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in…
- Trial name
- ENIGMA-TRS 2 (NCT07184619)
- Testing
- Evenamide 15 mg bid
- Where
- 19 sites in United States, Argentina and 2 more
- Volunteers
- 400 people
- Sponsor
- Newron Pharmaceuticals SPA
Chronic Schizophrenia, Schizoaffective Disorder
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or…
- Trial name
- NCT01450514
- Testing
- Pipamperone
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- PharmaNeuroBoost N.V.
Schizophrenia, Bipolar Disorder With Psychosis
Remote Cognitive Remediation
With medication, many individuals with psychosis experience a remission from hallucinations and delusions, the most salient aspects of the disorders.
- Trial name
- NCT02121106
- Testing
- Cognitive Remediation
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Queen's University
Healthy, Epilepsy
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
The human brain presents outstanding challenges to science and medicine. Brain function and structure span broad spatial scales (from single neurons to brain-wide networks) as well as temporal scales (from milliseconds to years).
- Conditions
- Healthy, Epilepsy, Psychosis, Essential Tremor
- Trial name
- NCT05769933
- Testing
- Simultaneous EEG-fMRI at 7 Tesla, Structural MRI at 7 Tesla
- Where
- Switzerland
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Developpement
Schizophrenia, Bipolar Disorder
Using Motivational Techniques to Increase Levels of Physical Activity in Long Term Psychiatric Inpatient Wards
The current research project aims at investigating whether it is possible to obtain an increase in physical activity among inpatients with schizophrenia spectrum disorders by the use of motivational interviewing and environmental…
- Conditions
- Schizophrenia, Bipolar Disorder, Inpatient Facility Diagnoses, Cardiovascular Risk Factor
- Trial name
- FYSAKT (NCT03528278)
- Testing
- Motivational interviewing and environmental interventions
- Where
- 2 sites in Norway
- Volunteers
- 83 people
- Sponsor
- Oslo University Hospital
Schizophrenia
Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia
The purpose of this study is to compare efficacy of quetiapine fumarate combined with Cognitive Remediation Therapy (CRT) to conventional treatment by evaluating change in social outcome in patients with schizophrenia.
- Trial name
- SCORE (NCT00255515)
- Testing
- Quetiapine fumarate, conventional treatment for schizophrenia
- Where
- 15 sites in Sweden
- Volunteers
- 85 people
- Sponsor
- AstraZeneca
Schizophrenia and Related Disorders, Sleep Disturbance
SPARK Healthy Sleep
SPARK-Healthy Sleep is a digital mental health intervention designed to help college students who may be at risk for psychosis and experience sleep problems.
- Trial name
- SPARK (NCT07119268)
- Testing
- SPARK Healthy Sleep
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Indiana University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.